logo
Plus   Neg
Share
Email

AstraZeneca, Amgen Announce Breakthrough Therapy Designation For Tezepelumab

AstraZeneca and Amgen Inc. (AMGN) announced the US FDA has granted Breakthrough Therapy Designation for tezepelumab in patients with severe asthma, without an eosinophilic phenotype, who are receiving inhaled corticosteroids/long-acting beta2-agonists with or without oral corticosteroids and additional asthma controllers.

The Breakthrough Therapy Designation is based on the tezepelumab Phase IIb PATHWAY data that showed a significant reduction in the annual asthma exacerbation rate compared with placebo in a broad population of severe asthma patients irrespective of patient phenotype including Type 2 biomarker status.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Walt Disney World is introducing a new ticket pricing system in order to better distribute attendance at its theme parks throughout the year. The company plans to begin pricing tickets for its theme parks based on dates so as to reflect the expected demand on specific days. Disney said Monday that beginning October 16, guests will be able to access its new online vacation-booking portal. Chipmaker Qualcomm Inc. (QCOM) has accused Apple Inc. (AAPL) of stealing confidential and trade secrets and giving it to rival chipmaker Intel Corp. (INTC). CNBC reports that Qualcomm has filed a lawsuit accusing Apple of stealing "vast swaths" of confidential information and trade secrets for the... Shares of Facebook Inc. are down more than 2 percent in Tuesday's trading after photo-sharing app Instagram's co-founders Kevin Systrom and Mike Krieger said they are leaving the company. Systrom, Instagram's chief executive, and Krieger, the chief technical officer, did not give a reason for stepping down, but said they are now "ready for our next chapter."
Follow RTT